Generate Biomedicines, Inc. (GENB) vs Lycia Therapeutics Inc. (LYCA)

Generate Biomedicines, Inc. GENB 13.06 +3.90%
Lycia Therapeutics Inc. LYCA 30.50 +5.90%

Generate Biomedicines, Inc. and Lycia Therapeutics Inc. are both Biotechnology companies. Generate Biomedicines, Inc. and Lycia Therapeutics Inc. are of similar size ($1.7B and $1.6B).

Metric	GENB	LYCA	Biotechnology median
P/E	n/m	—	10.60
P/S	51.24	—	9.40
P/B	3.65	—	2.13
Price to free cash flow	n/m	—	25.18
EV/EBITDA	n/m	—	0.66
EV/Sales	37.20	—	9.02
Earnings yield	(39.68%)	—	(32.88%)
Free cash flow yield	(33.02%)	—	(23.13%)

Metric	GENB	LYCA	Biotechnology median
Gross margin	100.00%	—	68.51%
Operating margin	(751.19%)	—	0.00%
Net margin	(781.10%)	—	0.00%
Free cash flow margin	(1,692.17%)	—	0.00%
Return on equity	0.00%	—	(51.96%)
Return on assets	(90.35%)	—	(46.06%)
Return on invested capital	0.00%	—	0.00%

Metric	GENB	LYCA	Biotechnology median
Revenue growth (TTM)	—	—	6.76%
EPS growth (last fiscal year)	(13.66%)	—	29.88%
Revenue growth, 5-year CAGR	—	—	9.75%
Net income growth, 5-year CAGR	—	—	0.00%

Metric	GENB	LYCA	Biotechnology median
Debt to equity	0.00	—	0.00
Current ratio	8.30	—	4.97
Net debt to EBITDA	0.97	—	1.01

Metric	GENB	LYCA	Biotechnology median
Dividend yield	—	—	0.41%
Payout ratio	—	—	—

Metric	GENB	LYCA	Biotechnology median
Market cap	1.61b	1.66b	161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack